Live intraday price
Compare with our price levels
Close 2026-09-30: $141.66 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Not in the buy zone yet — needs to drop 7.8% · 2 whales recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 2.3Moves ~$5.02 a day
⚖️ Positives and risks
- ●เซียนซื้อใหม่/ซื้อเพิ่มไตรมาสล่าสุด 2 ราย
- ●แนวโน้มระยะยาวเป็นขาขึ้น (เหนือ MA200 และ MA200 ชี้ขึ้น)
- ●แข็งแกร่งกว่าตลาด (S&P 500) +16% ใน 6 เดือน
- ●ราคาเป้าหมายนักวิเคราะห์เฉลี่ย 174.69 (upside +23%, 13 ราย)
- ●รายได้โต +3749% เทียบปีก่อน
- ●เซียนขายออก/ลดสัดส่วน 1 ราย: Joel Greenblatt (ลด)
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
PATEL DINESH V PH D · CEO · Director
2026-09-10 · 7,278 shares @ $144.10 · pre-planned sale (10b5-1)
PATEL DINESH V PH D · CEO · Director
2026-09-09 · 63,548 shares @ $146.18 · pre-planned sale (10b5-1)
PATEL DINESH V PH D · CEO · Director
2026-09-08 · 54,174 shares @ $145.87 · pre-planned sale (10b5-1)
PATEL DINESH V PH D · CEO · Director
2026-08-11 · 34,239 shares @ $148.52 · pre-planned sale (10b5-1)
PATEL DINESH V PH D · CEO · Director
2026-08-10 · 65,761 shares @ $149.11 · pre-planned sale (10b5-1)
Waddill William D. · Director
2026-06-23 · 9,000 shares @ $117.94 · pre-planned sale (10b5-1)
Waddill William D. · Director
2026-06-10 · 9,000 shares @ $107.68 · pre-planned sale (10b5-1)
Waddill William D. · Director
2026-05-29 · 9,000 shares @ $99.64 · pre-planned sale (10b5-1)
PATEL DINESH V PH D · CEO · Director
2026-05-12 · 75,000 shares @ $100.12
PATEL DINESH V PH D · CEO · Director
2026-05-12 · 75,000 shares @ $100.12 · pre-planned sale (10b5-1)
Giraudo Bryan · Director
2026-05-08 · 6,000 shares @ $100.00
Giraudo Bryan · Director
2026-05-08 · 5,130 shares @ $100.00
Giraudo Bryan · Director
2026-05-07 · 36,000 shares @ $100.14
Giraudo Bryan · Director
2026-05-07 · 12,000 shares @ $100.07
Ali Asif · CFO
2026-04-20 · 1,750 shares @ $105.47
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
The Peptide Boom That Isn’t About Your Muscles
The Wall Street Journal · 2026-09-25
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey · 2026-09-06
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Insider Monkey · 2026-09-04
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News
Simply Wall St. · 2026-09-01
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones
Simply Wall St. · 2026-09-01
🔬 Deep dive
For those who want the detailed numbers